Getting industry to tackle the superbugs
Antibiotic resistance is a global burden, both medical and economic — but the pharma industry hasn’t done much to curb the rise of superbugs. Why? Well, antibiotics are not particularly alluring from a commercial perspective.
There are, however, ways to incentivize drug makers to develop new antibiotics, opines one life science exec — those approaches just may require coordination from governments, hospitals, and insurers alike.
Peter Bak, vice president for life science strategy at Back Bay Life Science Advisors, lays out his thoughts.
.png)
No hay comentarios:
Publicar un comentario